论文部分内容阅读
目的观察不同剂量米非司酮治疗子宫肌瘤的效果。方法将48例子宫肌瘤患者随机分为2组(A组和B组),每组24例,进行前瞻性研究。A组患者每天服用米非司酮12.5mg,B组患者每天服用米非司酮25mg,连续服用3个月。分别于治疗前后使用B超测量子宫和肌瘤体积,同时检测血常规和肝、肾功能。结果 2组患者在治疗期间均出现闭经,贫血纠正。治疗3个月后,2组患者子宫和肌瘤体积均显著缩小A组患者肌瘤缩小25.36%(P<0.05),B组患者肌瘤缩小25.68%(P<0.05);2组间比较结果无统计学意义。结论米非司酮是治疗子宫肌瘤较为理想的药物,可以用于保守方法治疗子宫肌瘤,在临床取得满意疗效;米非司酮12.5mg每日口服是保守治疗子宫肌瘤的理想剂量。
Objective To observe the effect of different doses of mifepristone treatment of uterine fibroids. Methods 48 cases of uterine fibroids were randomly divided into two groups (group A and group B), 24 cases in each group, for prospective study. Patients in group A took mifepristone 12.5 mg daily and group B took mifepristone 25 mg daily for 3 months. Before and after treatment, respectively, the use of B-measuring uterine and fibroid volume, while testing blood and liver and kidney function. Results Both groups had amenorrhea and anemia correction during the treatment. After 3 months of treatment, the volume of uterus and fibroids in both groups were significantly reduced. The fibroids in group A decreased by 25.36% (P <0.05), and those in group B decreased by 25.68% (P <0.05). The results of comparison between the two groups No statistical significance. Conclusion Mifepristone is an ideal drug for the treatment of uterine fibroids and can be used conservatively in the treatment of uterine fibroids with satisfactory results in clinical practice. Mifepristone 12.5mg orally daily is the ideal dose for conservative treatment of uterine fibroids.